Drug Profile
Research programme: GPR119 protein agonists - Exelixis
Latest Information Update: 09 Mar 2011
Price :
$50
*
At a glance
- Originator Exelixis
- Class
- Mechanism of Action GPR119 protein agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Metabolic disorders
Most Recent Events
- 22 Feb 2011 Discontinued for Metabolic disorders in USA (unspecified route)
- 12 Dec 2008 Early research in Metabolic disorders in USA (unspecified route)